Interrupción de los agonistas beta2 de acción prolongada (ABAP) para niños con asma bien controlada con ABAP y corticosteroides inhalados
Appendices
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)
Electronic searches: core databases
| Database | Frequency of search |
| CENTRAL (Cochrane Library) | Monthly |
| MEDLINE (Ovid) | Weekly |
| EMBASE (Ovid) | Weekly |
| PsycINFO (Ovid) | Monthly |
| CINAHL (EBSCO) | Monthly |
| AMED (EBSCO) | Monthly |
Handsearches: core respiratory conference abstracts
| Conference | Years searched |
| American Academy of Allergy, Asthma and Immunology (AAAAI) | 2001 onwards |
| American Thoracic Society (ATS) | 2001 onwards |
| Asia Pacific Society of Respirology (APSR) | 2004 onwards |
| British Thoracic Society Winter Meeting (BTS) | 2000 onwards |
| Chest Meeting | 2003 onwards |
| European Respiratory Society (ERS) | 1992, 1994, 2000 onwards |
| International Primary Care Respiratory Group Congress (IPCRG) | 2002 onwards |
| Thoracic Society of Australia and New Zealand (TSANZ) | 1999 onwards |
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti‐asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1‐15
Filter to identify RCTs
1. exp "clinical trial [publication type]"/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1‐7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify trial reports from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenergic beta‐Agonists
#6 beta* NEAR agonist*
#7 LABA*:ti,ab
#8 *formoterol
#9 Foradil
#10 Oxis
#11 salmeterol
#12 vilanterol
#13 Serevent
#14 Seretide or Advair or Viani or Symbicort or Inuvair or Dulera or Adoair or Breo or Relvar
#15 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 withdraw*:ti,ab
#17 down‐titrat*:ti,ab
#18 discontinu*:ti,ab
#19 stop*:ti,ab
#20 cease*:ti,ab
#21 cessat*:ti,ab
#22 (step‐down or "step down"):ti,ab
#23 (reduc* or decreas*) NEAR (dose*):ti,ab
#24 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #4 and #15 and #24
[Note: in search line #1 MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
Results of the search and study selection process
| Stopping long‐acting beta2‐agonists (LABA) compared with continuing inhaled corticosteroids (ICS) + LABA for children with well‐controlled asthma | ||
| Patient or population: children (aged 18 years or younger) whose asthma is well controlled on combination ICS + LABA Settings: outpatient Intervention: stopping LABA Comparison: continuing ICS + LABA | ||
| Outcomes | No of Participants | Comments |
| Exacerbations requiring systemic corticosteroids | 0 (0) | No studies met the inclusion criteria for the review |
| Asthma control (validated scales) | 0 (0) | |
| Serious adverse events (all cause) | 0 (0) | |
| Quality of life (validated scales) | 0 (0) | |
| Exacerbations requiring hospitalisation or emergency department visit | 0 (0) | |
| Adverse events (all cause) | 0 (0) | |
| Withdrawals | 0 (0) | |
